ReviewJournal of clinical laboratory analysis2021
The role and significance of angiotensin-converting enzyme 2 peptides in the treatment of coronavirus disease 2019.
Review in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Molecular Analysis of Hot-Spot Regions of ACE2 and TMPRSS2 in SARS-CoV-2 "Invulnerable" Individuals.Cureus · 2023Article
- ACE2, a drug target for COVID-19 treatment?Irish journal of medical science · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the end of 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus (2019-nCoV) posed a serious threat to human health and life. Therefore, the discovery of drugs that can effectively prevent and treat COVID-19 is urgently warranted. In this article, the role and significance of angiotensin-converting enzyme 2 in drug development and the treatment of COVID-19 are discussed. It was found that the binding of ACE2 to SARS-CoV-2-RBD involved two core regions (31st and 353rd lysine) and 20 amino acids of the ACE2 protein. The mutation of these amino acids could lead to a great change of the binding ability of ACE2 and SARS-CoV-2-RBD. This information was important for us to find more efficient ACE2 peptides to block the 2019-nCoV infection. So during this study, we summarized the role of ACE2 in the regulation of 2019-nCoV infection and stress, and hypothesized that the development and optimization of ACE2 peptide can effectively block 2019-nCoV infection and reliably treat the COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.